Wednesday, October 14, 2026
Via News Knowledge File

Anthropic

organization80% conf.·synced Oct 14, 2026

AI company developing Claude AI assistant

50
sourced metrics
1880
relationships
20
stated objectives
8
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Backlog
21USD
New Customer Preference
73.3percent
Projected Ipo Valuation
2000USD
Potential Ipo Valuation
60USD
Exposed Assets Count
3000assets
Aws Spend Commitment
100USD
Market Cap
380000000000USD
⚠ sources conflictsource
Fundraising Valuation
2trillion_USD
Revenue Run Rate
7billion_USD
Revenue
10billion_USD
Acquisition Count
5acquisitions
Sep 29, 2026source
Cumulative Funding Raised
125USD
Sep 2, 2026source
Compute Capacity Secured
5gigawatts
Aug 31, 2026source
Acquisition Count This Year
5companies
Aug 24, 2026source
Purchase Consideration Rate
29percent
Jul 16, 2026source
Market Share
40percent
Jul 15, 2026source
Employee Count Growth Yoy
183percent
Jul 2, 2026source
Deepmind Hires Count
5employees
Jul 2, 2026source

Stated objectives

Complete $50 billion US data center buildout

source
target: 50 billion USD stated

Prove that superior orchestration of existing models can yield exponential productivity gains as alternative to trillion-dollar infrastructure build-outs

source
stated

Halt training or delete model weights if safety and security standards cannot be met

source
stated

Target users running Claude Code continuously in the background 24/7 with new rate limits

source
target: less than 5 percent of users affected stated

Race to develop expert-level and superhuman AI systems

source
stated

Expand Cowork beyond macOS to Windows and add cross-device sync, growing access beyond Claude Max subscribers

source
stated

Make working with Claude feel less like operating a tool and more like delegating to a colleague, targeting mainstream non-technical users

source
stated

Continue developing agent safety mechanisms including defenses against prompt injection attacks as an active area of development

source
stated

Anthropic reportedly targeting its own IPO

source
stated

Diversify compute supply beyond Nvidia by expanding use of Amazon Trainium and Google TPUs to reduce concentration risk and improve hardware availability

source
stated

Relationship graph · 1880 connections

Competes with
551
Developed by
477
Customer of
154
Invested in
140
Supplies to
120
Employs
115
regulates
62
Covered by
31

Via News coverage

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com